Limits...
Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus

Forest plot of survivin expression on osteosarcoma grade ((A), Enneking clinical stage; (B) Price’s grade).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588668&req=5

f2-medscimonit-21-2877: Forest plot of survivin expression on osteosarcoma grade ((A), Enneking clinical stage; (B) Price’s grade).

Mentions: Sixteen articles assessed the effect of survivin expression on Enneking clinical stage, containing 845 patients. No significant heterogeneity was observed between studies. We divided patients into 2 groups by Enneking clinical stage: I–IIa and IIb–III groups included 489 and 356 patients, respectively. We found that the frequency of survivin expression was much higher in the IIb–III group than in the I–IIa group (82.4% vs. 51.7%). Our result demonstrated that there was a significant difference in survivin expression between these 2 groups (OR=5.26, 95% CI=3.76–7.34, P<0.00001) in a fixed-effects model, as shown in Figure 2A. Six articles concerned the Price’s grade, including 302 patients. We also divided patients into 2 groups: the III group and the I+II group. Survivin expression was higher in the III group than that in the I+II group (80.8% vs. 66.2%). Our analysis showed that survivin expression was highest in the III group (OR=2.04, 95% CI=1.16–3.61, P=0.01), as shown in Figure 2B. These results indicate that survivin could be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.


Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

Forest plot of survivin expression on osteosarcoma grade ((A), Enneking clinical stage; (B) Price’s grade).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588668&req=5

f2-medscimonit-21-2877: Forest plot of survivin expression on osteosarcoma grade ((A), Enneking clinical stage; (B) Price’s grade).
Mentions: Sixteen articles assessed the effect of survivin expression on Enneking clinical stage, containing 845 patients. No significant heterogeneity was observed between studies. We divided patients into 2 groups by Enneking clinical stage: I–IIa and IIb–III groups included 489 and 356 patients, respectively. We found that the frequency of survivin expression was much higher in the IIb–III group than in the I–IIa group (82.4% vs. 51.7%). Our result demonstrated that there was a significant difference in survivin expression between these 2 groups (OR=5.26, 95% CI=3.76–7.34, P<0.00001) in a fixed-effects model, as shown in Figure 2A. Six articles concerned the Price’s grade, including 302 patients. We also divided patients into 2 groups: the III group and the I+II group. Survivin expression was higher in the III group than that in the I+II group (80.8% vs. 66.2%). Our analysis showed that survivin expression was highest in the III group (OR=2.04, 95% CI=1.16–3.61, P=0.01), as shown in Figure 2B. These results indicate that survivin could be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus